CompositionDexamethasone Sodium Phosphate (0.1 % w/w),Neomycin Sulphate (0.5 % w/w.)
SALT INFORMATIONDexamethasone Sodium Phosphate (0.1 % w/w) TYPICAL USAGE Anorexia in palliative care, congenital adrenal hyperplasia, dyspnoea, dyspnoea in palliative care, headache due to raised intracranial pressure in palliative care, nausea and vomiting (chemotherapy induced), pain due to nerve compression in palliative care, raised intracranial pressure, respiratory distress syndrome, shock, suppression of inflammatory and allergic disorders. SIDE EFFECTS Glaucoma, peptic ulceration, myopathy, osteoporosis, growth retardation, aseptic bone necrosis, ocular hypertension, subcapsular cataract, pancreatic disturbance, cushing like features, oedema, retinal detachment, nausea, vomiting, insomnia, nervousness, nocturia, increased appetite, obesity, facial rounding, fragility of skin, euphoria, glucose intolerance. DRUG INTERACTION Tell your doctor of all prescription and nonprescription medication you may use. Do not start or stop any medicine without doctor or pharmacist approval. MECHANISM OF ACTION Dexamethasone is a glucocorticoid agonist. Unbound dexamethasone crosses cell membranes and binds with high affinity to specific cytoplasmic glucocorticoid receptors. This complex binds to DNA elements (glucocorticoid response elements) which results in a modification of transcription and, hence, protein synthesis in order to achieve inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of inflammatory response, suppression of humoral immune responses, and reduction in edema or scar tissue. The antiinflammatory actions of dexamethasone are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Neomycin Sulphate (0.5 % w/w.) TYPICAL USAGE Decontamination of digestive tract, hepatic coma, hepatic encephalopathy, pre-operative bowel sterilization, sepsis, skin infections SIDE EFFECTS Urticaria, angioneurotic edema, ototoxicity, blood dyscrasias, anaphylactic shock, renal failure, vertigo, headache, diarrhea, tinnitus, pruritus, lethargy, skin rash, contact dermatitis. DRUG INTERACTION Neomycin is known to interact with other drugs like acarbose, atracurium (Besylate), cyanocobalamin, digoxin, doxacurium, fluorouracil, gentamicin, gestodene, hydroxocobalamin, mecobalamin, methotrexate, pancuronium (Br). Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required. MECHANISM OF ACTION Neomycin irreversibly bind to specific 30S-subunit proteins and 16S rRNA. Specifically neomycin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes.